Supernus Pharma (SUPN) Misses Q3 EPS by 31c

Supernus Pharma (NASDAQ: SUPN) reported Q3 EPS of ($0.29), $0.31 worse than the analyst estimate of $0.02. Revenue for the quarter came in at $153.88 million versus the consensus estimate of $144.94 million.

For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.

You May Also Be Interested In

• SolarEdge (SEDG) PT Lowered to $31 at Jefferies, 'We see shares as an unappealing short, not a compelling long'
• Dollar General stock jumps on earnings beat and raised guidance
• Titan Machinery (TITN) Misses Q2 EPS by 5c ; Offers Guidance